Paul Mampilly’s take on precision medicine stocks

Paul Mampilly’s take on precision medicine stocks

Paul Mampilly, senior editor at Banyan Hill says he has pinpointed the Company that is leading in precision medicine revolution.

In his Profits Unlimited newsletter, Paul Mampilly further states that this company will be a major player and leap big in the healthcare industry because it extensively covers many aspects of the medicine market. Visit Bloomberg to know more about Paul Mampilly.

The company, Myriad Genetics is based in Utah near Salt Lake City and is worth around $1.5 billion. It is led by a twenty-five years old C.E.O. who happens to be a biotech pioneer and as such he boasts the proficiency required in the sector.

According to a publication by Paul Mampilly in his Profits Unlimited newsletter, the company will enable the treatment of previously untreatable diseases as it goes the extra mile by giving treatments and prescription based on an individual’s DNA structure.

Severe chronic diseases like arthritis, Parkinson’s, diabetes, Alzheimer’s and heart diseases will now be reduced immensely thanks to the technology from Myriad Genetics.

Paul Mampilly states that precision medicine will enable doctors to correctly establish which treatments and antibiotics will be the best in preventing a patient from contracting a particular illness. Watch videos on Paul’s Youtube channel.

He further adds that based on a person’s DNA and Genes, doctors will be able to precisely prescribe the best medicine that will cure an existing disease.

Myriad Genetics

Myriad Genetics is leading the medical industry in the fight against cancer. Breast cancer, ovarian cancer, lung cancer, uterine and rheumatoid arthritis, are among the major diseases the company is targeting to find a solution for.

In his publication, Paul Mampilly says that the company will be able to predict whether someone will contract diseases and also establish which medication will work best for the person.

The company will achieve this by performing molecular diagnostic DNA, which is a faculty the company is way ahead in the medical field.

Myriad Genetics has over the past years specialized in cancer screening and predicting treatment programs. The company also offers hereditary cancer screening, especially in breast and colon cancer.

Through their tests, they are able to identify individuals with mutations that enhance their risk of getting a specific type of cancer. They also come up with prevention options for such people at an early-stage. All these are sufficient proof that purchasing stakes in Myriad genetics will be a wise move because traders will have higher chances of reaping abundant profits.

More about Paul Mampilly

Paul Mampilly joined Banyan Hill Publishing back in 2016 and now serves as the senior editor.

His specialty is helping Americans spot investments in stocks and technology and wealth opportunities outside Wall Street. He began his career as a junior portfolio manager in 1991 at Bankers Trust, in Wall Street.

He later worked at Deutsche Bank and ING where he was in charge of multimillion-dollar investments Paul later quit Wall Street because he felt he was only making money for the few rich people in the country.

Today Mr. Mampilly specializes in helping financially average people to identify suitable investment opportunities is that will help people when they retire. He is the founder of Profits Unlimited and Extreme Fortunes newsletters which is doing extremely well and has over 60,000 subscribers.



Add Your Comment: